Phase I Study for Autologous Dermal Substitutes and Dermo-epidermal Skin Substitutes for Treatment of Skin Defects

Inclusion Criteria: * Deep partial or full thickness skin defect of at least 9 cm2 requiring surgical wound coverage due to: 1. Acute cases: burn injury, soft tissue injury, skin necrosis after purpura fulminans 2. Reconstructive cases (elective surgery): scar formation after burn injuries, congenital giant nevus, skin tumours * Informed consent by patients/parents or other legal representatives Exclusion Criteria: * Infected wounds or positive general microbiological swabs taken from the nose for multi-resistant germs * Patients tested positive for HBV, HCV, syphilis or HIV * Patients with known underlying or concomitant medical conditions that may interfere with normal wound healing (e.g. immune deficiency, systemic skin diseases, any kind of congenital defect of metabolism including diabetes) * Coagulation disorders as defined by INR outside its normal value, PTT \>ULN and fibrinogen \<LLN and / or at the Investigator's discretion * Previous enrolment of the patient into the current study * Participation of the patient in another study within 30 days preceding and during the present study * Patients or parents/other legal representatives expected not to comply with the study protocol * Suspicion of child abuse * Pregnant or breast feeding females * Contamination derived from biopsy which could interfere with patients health * Due to patient derived variations, isolated cells from biopsy do not proliferate or proliferate insufficiently * Skin substitute has not been released due to production specific deviations * Patients allergic to amphotericin B and gentamicin